FGP
IART icon

Freestone Grove Partners’s Integra LifeSciences IART Stock Holding History

Freestone Grove Partners’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$9 – 1168
2026
Q1 		$9 Buy
+1
New +$11 ﹤0.01% 949

Other funds holding IART

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Freestone Grove Partners's IART Position: Q2 2026 in Review

Freestone Grove Partners sold out of Integra LifeSciences (IART) in Q2 2026, closing a stake of 1 share — an estimated $9 sold.

Freestone Grove Partners first reported a position in IART in Q1 2026 and held it in 1 quarter. The position peaked at $9 in Q1 2026. 213 funds tracked by Wall St. Rank hold IART as of Q2 2026.

  • Freestone Grove Partners reported no remaining Integra LifeSciences position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 1 Integra LifeSciences share in Q2 2026, an estimated $9.
  • Freestone Grove Partners first reported a position in Integra LifeSciences in Q1 2026 and held it in 1 quarter.
  • Freestone Grove Partners's Integra LifeSciences position peaked at $9 in Q1 2026.
  • 213 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.